Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.35 |
| ▸ | OGA | O60502 | 7/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18335149 | 0.82 | EGLN1 (0.49) | EGLN1CHRNB2CHRNA2CHRNB4CHRNA3 | |
| SCHEMBL19063456 | 0.80 | EGLN1 (0.46) | EGLN1EGLN3GRM5 | |
| SCHEMBL18335073 | 0.77 | EGLN1 (0.44) | EGLN1CHRNB2CHRNA2CHRNB4CHRNA3 | |
| SCHEMBL18335098 | 0.77 | EGLN1 (0.44) | EGLN1CHRNB2CHRNA2CHRNB4CHRNA3 | |
| SCHEMBL18335169 | 0.77 | EGLN1 (0.40) | EGLN1CHRNB2CHRNA2CHRNB4CHRNA3 | |
| SCHEMBL15900548 | 0.75 | EGLN1 (0.53) | EGLN1CHRNB2CHRNA2CHRNB4CHRNA3 | |
| SCHEMBL16432336 | 0.74 | FFAR1 (0.42) | EGLN1GRM5FFAR1PTGESBACE1 | |
| SCHEMBL18335118 | 0.73 | EGLN1 (0.41) | EGLN1GRM5 | |
| SCHEMBL31044571 | 0.72 | EGLN1 (0.50) | EGLN1CHRNB2CHRNA2CHRNB4CHRNA3 | |
| SCHEMBL18335074 | 0.72 | MEN1 (0.46) | EGLN1CHRNB2CHRNA2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10231454-B2 | Fungicidal or bactericidal composition, and method for controlling diseases | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2019-03-19 | — | — | US | disclosed |
| US-20180220655-A1 | FUNGICIDAL OR BACTERICIDAL COMPOSITION, AND METHOD FOR CONTROLLING DISEASES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-08-09 | — | — | US | disclosed |
| US-9974305-B2 | Fungicidal or bactericidal composition, and method for controlling diseases | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20170188580-A1 | FUNGICIDAL OR BACTERICIDAL COMPOSITION, AND METHOD FOR CONTROLLING DISEASES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180220655-A1 | FUNGICIDAL OR BACTERICIDAL COMPOSITION, AND METHOD FOR CONTROLLING DISEASES | NOX3, TH, CBR3 | EGLN1 238/4885CHRNB2 1827/4885CHRNA2 2894/4885 |
| US-10231454-B2 | Fungicidal or bactericidal composition, and method for controlling diseases | NOX3, TH, CBR3 | EGLN1 238/4885CHRNB2 1827/4885CHRNA2 2894/4885 |
| US-20170188580-A1 | FUNGICIDAL OR BACTERICIDAL COMPOSITION, AND METHOD FOR CONTROLLING DISEASES | NOX3, TH, CBR3 | EGLN1 238/4885CHRNB2 1827/4885CHRNA2 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.